Marshall Wace
CYCN icon

Marshall Wace’s Cyclerion Therapeutics CYCN Stock Holding History

Marshall Wace’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-522
Closed -$18K – 3463
2021
Q4 		$18K Buy
+522
New +$24.7K ﹤0.01% 3713
2021
Q3 		– Sell
-1,443
Closed -$113K – 3080
2021
Q2 		$113K Buy
+1,443
New +$90.3K ﹤0.01% 2529

Other funds holding CYCN

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Marshall Wace's CYCN Position: Q1 2022 in Review

Marshall Wace sold out of Cyclerion Therapeutics (CYCN) in Q1 2022, closing a stake of 522 shares — an estimated $18K sold.

Marshall Wace first reported a position in CYCN in Q2 2021 and held it in 2 quarters. The position peaked at $113K in Q2 2021. 50 funds tracked by Wall St. Rank hold CYCN as of Q1 2022.

  • Marshall Wace reported no remaining Cyclerion Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Marshall Wace sold 522 Cyclerion Therapeutics shares in Q1 2022, an estimated $18K.
  • Marshall Wace first reported a position in Cyclerion Therapeutics in Q2 2021 and held it in 2 quarters.
  • Marshall Wace's Cyclerion Therapeutics position peaked at $113K in Q2 2021.
  • 50 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q1 2022.

Based on Marshall Wace's 13F filing for Q1 2022, filed 16 May 2022.